Loading clinical trials...
Loading clinical trials...
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
Conditions
Interventions
Elagolix
Placebo
Locations
54
United States
Alabama Clinical Therapeutics /ID# 211498
Birmingham, Alabama, United States
Mobile, OBGYN P.C. /ID# 205574
Mobile, Alabama, United States
Medical Ctr for Clin Research /ID# 205694
San Diego, California, United States
UCSF Center for Reproductive Health /ID# 210836
San Francisco, California, United States
Avail Clinical Research /ID# 210873
DeLand, Florida, United States
University of FL Southside Women's Specialists /ID# 210872
Jacksonville, Florida, United States
Start Date
August 12, 2019
Primary Completion Date
February 10, 2021
Completion Date
February 10, 2021
Last Updated
June 8, 2022
NCT07483723
NCT06793098
NCT06793085
NCT06047574
NCT07385716
NCT06800170
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions